ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer

This study has been terminated.

(low accrual)

Sponsor:

Collaborator:

Breast International Group

Information provided by (Responsible Party):

European Organisation for Research and Treatment of Cancer - EORTC

ClinicalTrials.gov Identifier:

NCT00010153

First received: February 2, 2001

Last updated: July 18, 2012

Last verified: July 2012

History of Changes

Purpose

RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ICI 182780 before surgery may block the uptake of estrogen by the tumor cells and prevent metastases. It is not yet known if ICI 182780 is effective in preventing breast cancer metastases.

PURPOSE: Randomized phase III trial to study the effectiveness of ICI 182780 given before surgery in treating women who have stage I or stage II primary breast cancer.

Condition	Intervention	Phase
Breast Cancer	Drug: fulvestrant Procedure: conventional surgery	Phase 3


Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	A Double-Blind Phase III Clinical Trial to Compare the Effects of a Pre-Operatively Administered Single Dose of "Faslodex" (Long-Acting ICI 182.780) With Placebo on Tumor Recurrence in Pre- and Postmenopausal Women Treated for Operable First Primary Breast Cancer

Resource links provided by NLM:

Genetics Home Reference related topics: breast cancer

MedlinePlus related topics: Breast Cancer

Drug Information available for: Fulvestrant

U.S. FDA Resources

Further study details as provided by European Organisation for Research and Treatment of Cancer - EORTC:


Study Start Date:	November 2000
Primary Completion Date:	October 2001 (Final data collection date for primary outcome measure)

Detailed Description:

OBJECTIVES:

Determine the inhibitory effect of ICI 182780 on the development of metastasis, as measured by disease-free survival and overall survival, in women with operable stage I or II primary breast cancer.
Determine toxicity of this regimen in these patients.

OUTLINE: This is a randomized, double-blind, placebo-controlled, multicenter study. Patients are stratified according to participating center and menopausal status (premenopausal vs postmenopausal).

Patients are randomized to receive either ICI 182780 IM or placebo IM over 2 minutes on day 1. Patients undergo surgery between days 8 and 29.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

PROJECTED ACCRUAL: A total of 3,656 patients (1,828 per arm) will be accrued for this study within 2 years.

Eligibility


Ages Eligible for Study:	Child, Adult, Senior
Sexes Eligible for Study:	Female
Accepts Healthy Volunteers:	No

Criteria

DISEASE CHARACTERISTICS:

Histologically or cytologically confirmed stage I or II primary operable breast cancer
- Surgery planned within next 1-4 weeks
Hormone receptor status:
- Estrogen receptor positive or unknown
- No known estrogen receptor negative tumor
- Unknown progesterone receptor status eligible

PATIENT CHARACTERISTICS:

Age:

Any age

Sex:

Female

Menopausal status:

Premenopausal or postmenopausal

Performance status:

Not specified

Life expectancy:

Not specified

Hematopoietic:

No bleeding diathesis not compatible with an IM depot injection

Hepatic:

Not specified

Renal:

Not specified

Other:

Not pregnant
Negative pregnancy test
Fertile patients must use effective non-hormonal contraception during and for 2-3 months after study
No other prior or concurrent malignancy except adequately treated basal cell carcinoma of the skin or cancer of the uterine cervix
No psychological, familial, sociological, or geographical condition that would preclude study

PRIOR CONCURRENT THERAPY:

Biologic therapy:

Not specified

Chemotherapy:

Not specified

Endocrine therapy:

At least 2 months since prior ICI 182780

Radiotherapy:

No prior radiotherapy to primary tumor

Surgery:

See Disease Characteristics

Other:

No other concurrent preoperative therapy for breast cancer

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00010153

Locations


United Kingdom
Christie Hospital N.H.S. Trust
Manchester, England, United Kingdom, M20 4BX

Sponsors and Collaborators

European Organisation for Research and Treatment of Cancer - EORTC

Breast International Group

Investigators


Study Chair:	Cornelis J.H. van de Velde, MD, PhD, FRCS, FRCPS	Leiden University Medical Center
Study Chair:	Anthony Howell, MD	The Christie NHS Foundation Trust

More Information


Responsible Party:	European Organisation for Research and Treatment of Cancer - EORTC
ClinicalTrials.gov Identifier:	NCT00010153 History of Changes
Other Study ID Numbers:	EORTC-10963 BIG-EORTC-10963
Study First Received:	February 2, 2001
Last Updated:	July 18, 2012

Keywords provided by European Organisation for Research and Treatment of Cancer - EORTC:


stage I breast cancer stage II breast cancer

Additional relevant MeSH terms:


Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Fulvestrant Antineoplastic Agents, Hormonal	Antineoplastic Agents Estrogen Receptor Antagonists Estrogen Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 27, 2017

To Top